Antonio Guzzi

Dr. Antonio Guzzi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
FSFranz Schnetzinger
Franz Schnetzinger
DCDidier Clenet
Didier Clenet
PGPhilippe-Alexandre Gilbert
Philippe-Alexandre Gilbert
AGAntonio Guzzi
Antonio Guzzi
MPMarilena Paludi
Marilena Paludi
RHRenske Hesselink
Renske Hesselink
The rapid development of equitably accessible vaccines is paramount in addressing emerging global health challenges. The safety and efficacy of vaccines hinge significantly on their ability to remain stable from manufacturing throughout the supply chain and up to administration. Furthermore, the release of vaccines requires sufficient understanding of the stability profile to allow for expiration dating. In the event of a public health crisis, the time to generate the necessary stability data and the need for rapid product release are in direct opposition. Developing manufacturing platforms with thermostable product formulations for rapid response is therefore key to meeting CEPI’s 100 Days Mission goal. This Review aims to highlight the need for stability preparedness through developing thermostable vaccine platforms and exploring innovative stability monitoring strategies that leverage advanced technologies, predictive modelling, and adaptive methodologies. By doing so, we seek to enhance the efficiency and effectiveness of stability assessments, supporting rapid development, regulatory approval, and widespread, equal distribution of vaccines—especially in an outbreak scenario. Finally, enhanced thermostability will allow for simplification across the supply chain, which will reduce the financial burden of vaccination programmes and enhance equitable access.

25 July 2024 in PDA Journal of Pharmaceutical Science and Technology
Verified
Journal Article
Closed access
PDF file
ASAnna Saernefaelt
Anna Saernefaelt
RERanna Eardley-Patel
Ranna Eardley-Patel
DMDiletta Magini
Diletta Magini
VSVishal Sonje
Vishal Sonje
AGAntonio Guzzi
Antonio Guzzi
IKIngrid Kromann
Ingrid Kromann
The Coalition for Epidemic Preparedness Innovations (CEPI) has developed a robust CMC (Chemistry, Manufacturing, and Controls) Framework to enhance the likelihood of successful vaccine development. This Framework serves as a comprehensive guide, aiding developers in building effective strategies to overcome the challenges posed by the different phases of vaccine development, including the ones often referred to as the "valleys of death". The Framework lists stage-appropriate deliverables, categorized and refined, spanning five key areas: manufacturing process, formulation and stability, analytics, supply chain, and compliance. By emphasizing the critical aspects of CMC development, CEPI9s objective is to expedite the progression of vaccine candidates from research to deployment, reducing delays, mitigating risks, and optimizing the overall development process, all while upholding uncompromising quality standards, ultimately increasing the probability of success.

31 January 2025 in Vaccine
Verified
Journal Article
Open access
MMMic McGoldrick
Mic McGoldrick
TTTran Ba Quang Truong
Tran Ba Quang Truong
CCCristiana Campa
Cristiana Campa
MAMurtuza Ali
Murtuza Ali
AGAntonio Guzzi
Antonio Guzzi
JEJennifer Eck
Jennifer Eck
When the Covid-19 pandemic was declared by WHO, a team of vaccine manufacturers worked with the COVAX (COVID-19 Vaccine Global Access) Manufacturing SWAT (Support Work to Advance) team to propose regulatory agilities for accelerating access to vaccines. The cooperation and success demonstrated during the pandemic demonstrated the benefits of simplifying requirements and reliance. Vaccine developers, manufacturers, the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders have engaged in discussions to highlight the lessons learned from this experience and to find solutions to address those challenges. This paper discusses efforts to accelerate pandemic preparedness and reports a comparative assessment of early and later pandemic experiences from vaccine manufacturers. The lessons learned and the risk-based approaches were invaluable in bringing vaccines to patients. However, the shift from cooperative pandemic pathways to strict non-pandemic requirements can impact supply. Flexibility and reliance are still needed to ensure timely product availability. This article emphasizes the importance of continuing pandemic preparedness and acting on lessons learned.